Euflexxa is a three-injection, non-animal sourced hyaluronic acid viscosupplement used for the symptomatic treatment of knee osteoarthritis pain. Manufactured by Ferring Pharmaceuticals, Euflexxa is one of the most clinically studied viscosupplementation products available and is widely used by orthopaedic, sports medicine, and pain management practitioners. This guide covers everything practitioners need to know about Euflexxa: formulation, mechanism of action, dosing protocol, injection technique, side effects, expected outcomes, patient selection, and how it compares to other viscosupplements.

What Is Euflexxa?

Euflexxa (1% sodium hyaluronate) is a sterile, viscoelastic, non-pyrogenic solution of high-molecular-weight hyaluronic acid derived from bacterial fermentation. Its non-animal origin eliminates the risk of avian hypersensitivity reactions associated with products such as Synvisc or Hyalgan, making it suitable for patients with bird or egg allergies.

Key product specifications:

  • HA concentration: 10 mg/ml (1%)
  • Volume per injection: 2 ml (20 mg per injection)
  • Injections per course: 3 weekly injections
  • Molecular weight: 2.4-3.6 million Daltons (high molecular weight)
  • Origin: Non-animal, bacterial fermentation derived
  • Regulatory status: FDA-cleared (US), CE-marked (Europe)

Licensed practitioners can order Euflexxa at wholesale prices from Bioresus via the Euflexxa product page, alongside the full range of orthopaedic injectables.

How Does Euflexxa Work?

In a healthy joint, synovial fluid provides both lubrication and shock absorption through its viscoelastic properties, which depend on the concentration and molecular weight of naturally occurring hyaluronic acid. In osteoarthritis, both the concentration and molecular weight of synovial HA decrease, resulting in reduced viscosity, increased joint friction, pain, and progressive cartilage damage.

Euflexxa restores the viscoelastic properties of synovial fluid through several mechanisms:

  • Supplements and replaces degraded natural HA in the joint space
  • Reduces friction between articular cartilage surfaces during weight-bearing activities
  • Absorbs mechanical shock, protecting the remaining cartilage
  • May exert anti-inflammatory effects by binding to surface receptors on synoviocytes and chondrocytes
  • May stimulate endogenous HA production within the joint over time

Euflexxa’s high molecular weight HA closely mimics healthy native synovial HA, which is why it demonstrates favourable rheological properties in vitro and strong clinical outcomes in pivotal trials.

Indications for Euflexxa Injection

  • Symptomatic knee osteoarthritis (Kellgren-Lawrence Grade I-III)
  • Adults who have not responded adequately to conservative management (physiotherapy, weight management, NSAIDs, or analgesics)
  • Patients seeking a non-surgical, non-opioid pain management option
  • Patients wishing to delay or avoid total knee replacement surgery
  • Active patients (athletes, manual workers) requiring pain control without systemic medication
  • Patients with bird or egg allergy who require a non-avian sourced viscosupplement

Contraindications

  • Known hypersensitivity to hyaluronic acid or any component of the formulation
  • Active infection in or around the knee joint
  • Skin disease or active infection at the proposed injection site
  • Venous or lymphatic stasis in the affected limb
  • Pregnancy or lactation (limited safety data available)

Use with caution in patients on anticoagulant therapy. A minimum washout period of 4-6 weeks between intra-articular corticosteroid and HA injections is generally recommended to avoid diminished response.

Euflexxa Dosage and Treatment Protocol

Standard Dosing

  • Three intra-articular injections of 2 ml (20 mg sodium hyaluronate) into the affected knee
  • Administered at weekly intervals (7-day spacing recommended)
  • Re-treatment may be considered 6 months after the initial course, based on clinical assessment

The three-injection protocol differs from single-injection alternatives such as Monovisc or Durolane. For practices where patient compliance with multiple visits is a concern, a single-injection product may be more appropriate. However, the staged approach allows clinical reassessment between injections and may be preferred in patients where a more gradual introduction of HA therapy is warranted.

Re-Treatment Considerations

Document baseline and follow-up pain scores (VAS/NRS) and functional status (WOMAC or KOOS) before and after each treatment course to make evidence-based re-treatment decisions. Most patients who respond to Euflexxa maintain relief for 6 months; some responders sustain benefit for up to 12 months.

Euflexxa Injection Technique

Equipment Required

  • Euflexxa 2 ml prefilled syringe
  • 21-23 gauge needle (not supplied)
  • Sterile gloves and draping
  • Antiseptic skin preparation solution (chlorhexidine or povidone-iodine)
  • Optional: local anaesthetic (lidocaine 1%) for patient comfort

Injection Approaches

Superolateral approach (most common for patients in full extension):

  • Patient supine with knee fully extended
  • Insert needle superior and lateral to the patella, directing medially and slightly inferiorly into the joint space
  • Aspirate any significant joint effusion before injecting Euflexxa to maximise therapeutic effect
  • Inject 2 ml slowly and evenly; stop immediately if resistance is felt

Anteromedial or anterolateral approach (knee flexed at 90 degrees):

  • Patient seated with knee bent at 90 degrees
  • Insert needle adjacent to the patellar tendon, medially or laterally
  • Suitable for patients with difficulty achieving full extension

Ultrasound guidance is strongly recommended for all viscosupplementation injections. Multiple studies demonstrate that ultrasound-guided intra-articular knee injections achieve significantly higher accuracy rates compared to landmark-guided techniques, particularly in obese patients or those with anatomical variation.

Post-Injection Care

  • Advise patients to avoid strenuous physical activity and prolonged weight-bearing for 48 hours post-injection
  • Ice application to the knee for 15-20 minutes may reduce immediate discomfort and swelling
  • Mild swelling, warmth, or stiffness for 24-72 hours is expected and typically self-limiting
  • Onset of pain relief typically takes 4-8 weeks; patients should not assess efficacy before this time
  • Ensure patients understand they need to return for all three injections to complete the course
  • Schedule a follow-up at 8-12 weeks after the final injection to assess response

Euflexxa Side Effects and Safety Profile

Common (Local, Transient)

  • Injection site pain — most frequently reported, typically mild and short-lived
  • Swelling or joint effusion — usually resolves within 48-72 hours
  • Warmth and redness around the knee
  • Temporary increased joint stiffness post-injection

Serious (Rare)

  • Septic arthritis — risk is minimised with strict aseptic technique; urgent evaluation required if fever, rapidly worsening joint pain, or systemic signs develop post-injection
  • Acute inflammatory (pseudoseptic) reaction — characterised by sudden joint pain and swelling within 24-72 hours; typically self-limiting
  • Hypersensitivity reactions — rare with non-animal sourced HA, but practitioners should be prepared to manage anaphylaxis

Instruct patients to contact the clinic immediately if post-injection pain worsens rather than improves after 72 hours, or if they develop fever, significant joint swelling, or systemic symptoms.

Expected Clinical Outcomes

Euflexxa’s efficacy has been established in pivotal randomised controlled trials including the FLEXX trial (one of the largest intra-articular HA trials to date):

  • Significant reductions in WOMAC pain scores compared to saline control at 26 weeks
  • Clinically meaningful improvements in WOMAC physical function subscales
  • Pain relief sustained for up to 6 months in responding patients
  • Responder rates of approximately 60-70% in mild-to-moderate OA patients
  • Non-inferiority demonstrated against Synvisc in head-to-head studies

As with all viscosupplementation products, outcomes are best in patients with Kellgren-Lawrence Grade II-III OA. Patients with severe Grade IV (bone-on-bone) OA are unlikely to achieve meaningful benefit and should be counselled accordingly.

Euflexxa vs Other Viscosupplements

When selecting a viscosupplement, practitioners should weigh injection schedule, HA origin, molecular weight, and patient-specific factors:

  • Euflexxa vs Monovisc: Both are non-animal sourced. Monovisc is a single-injection product (88 mg/4 ml); Euflexxa requires 3 injections but allows staged clinical reassessment.
  • Euflexxa vs Durolane: Durolane is a single-injection, NASHA-technology product (60 mg/3 ml). Euflexxa’s 3-injection protocol allows interim reassessment; Durolane is more convenient for patients prioritising minimal clinic visits.
  • Euflexxa vs Orthovisc: Both are 3-injection, non-animal sourced products. Orthovisc has a higher molecular weight (1-2.9 million Da vs 2.4-3.6 million Da for Euflexxa); clinical outcomes are broadly comparable.
  • Euflexxa vs Synvisc: Synvisc is an avian-derived hylan product and carries a higher allergy risk. Euflexxa is non-animal sourced and is the preferred option for patients with bird or egg allergy.
  • Euflexxa vs Supartz FX: Supartz FX is a 5-injection avian-derived product. Euflexxa’s shorter 3-injection protocol and non-animal origin give it a clinical advantage in most practice settings.

Patient Selection and Counselling

Ideal Candidates

  • Kellgren-Lawrence Grade II-III knee OA
  • Patients unresponsive to conservative management after an adequate trial
  • BMI under 35 (higher BMI is associated with lower response rates)
  • Patients with bird or egg allergy requiring a non-avian sourced HA product
  • Patients and practices comfortable with a 3-visit injection protocol

Key Counselling Points

  • Euflexxa provides symptomatic relief, not disease modification — it does not reverse cartilage damage
  • Three clinic visits over three weeks are required to complete the initial course
  • Onset of meaningful pain relief typically takes 4-8 weeks from the final injection
  • Duration of effect is typically 6 months; re-treatment can be considered at that point
  • Non-response is possible — approximately 30-40% of patients do not achieve clinically meaningful relief

Ordering Euflexxa Wholesale

Licensed practitioners can order Euflexxa at wholesale prices from Bioresus. Browse the full orthopaedic injectables range, including Euflexxa, Monovisc, Durolane, Orthovisc, and Supartz FX. All products are sourced from authorised distributors and supplied with full documentation to support practice compliance requirements.

Conclusion

Euflexxa is a clinically well-supported, non-animal sourced viscosupplement with a strong safety and efficacy profile suitable for a wide patient population. Its three-injection protocol allows staged clinical management, and its non-avian origin makes it the product of choice for patients with relevant allergies. For practices already offering other viscosupplements such as Monovisc or Orthovisc, adding Euflexxa broadens the clinical options available and allows more precise tailoring of treatment to individual patient needs and preferences.